Whether or not the factor VII Gla-domain is involved in the high-affinity interaction of factor VII and tissue factor via calcium-dependent interactions with surrounding phospholipids is unknown. To investigate this, we have purified the factor VII Gla-peptide (FVII-GP) from digested recombinant human factor VII a and assessed its effect on factor VII: tissue factor interactions. FVII-GP inhibited the activation of factor X by factor Vila in the presence of either soluble or cell surface tissue factor halfmaximally at 0.5 μM and 2.7 μM, respectively. However, FVII-GP failed to inhibit the specific binding of factor Vila to cell-surface tissue factor, and did not inhibit the ability of tissue factor to stimulate the amidolytic activity of factor Vila. Unrelipidated tissue factor apoprotein stimulated the amidolytic activity of factor Vila to the same extent as relipidated tissue factor apoprotein. These findings suggest that the factor VII Gla-domain does not directly interact with tissue factor, but rather is important for calcium binding and concomitant expression of other factor VII epitopes necessary for tissue factor recognition and binding. To test this hypothesis, we have prepared a monoclonal antibody against a putative factor VII epitope that participates in the interaction of factor VII with cell-surface tissue factor (peptide 195-206) and assessed its ability to bind to factor VII in the presence and absence of calcium. Binding of this monoclonal antibody (PW-4) to intact factor VII a was calcium-dependent and could be inhibited in a dose-dependent manner by peptide 195-206. The antibody reacted with Gla-domainless factor Vila, but only 37% as compared to intact factor Vila. In addition, PW4 as well as its Fab’ fragment, inhibited factor Vila binding to cell-surface tissue factor. These studies indicate that the factor VII Gla-domain does not provide structural elements that contribute to the formation of a stable factor VII/VII a-tissue factor binary complex. The factor VII Gla-domain appears to be necessary, however, in binding calcium ions and inducing a calcium-dependent conformational change in factor VII/VII a that expresses one or more neoepitopes that participates in the interaction of factor VII/VII a with the extracellular domain of tissue factor apoprotein.
References
1
Hagen FS,
Gray CL,
O’Hara P,
Grant FJ,
Saari GC,
Woodbury RG,
Hart CE,
Insley M,
Kisiel W,
Kurachi K,
Davie EW.
Caracterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 2412-2416
4
Sakai T,
Lund-Hansen T,
Thim L,
Kisiel W.
The ³-carboxyglutamic acid domain of factor VII a is essential for its interaction with cell surface tissue factor. J Biol Chem 1990; 276: 1890-1894
5
Bradford MM.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248-254
9
Fraker PJ,
Speck JC.
Protein and cell membrane iodinations with a sparingly soluble chloroamide, l,3,4,6-tetrachloro-3a, 6a-diphenylgly-couril. Biochem Biophys Res Commun 1978; 80: 849-857
10
Thim L,
Bjoern S,
Christensen M,
Nicolaisen EM,
Lund-Hansen T,
Pedersen AH,
Hedner U.
Amino acid sequence and posttranslational modifications of human factor VII a from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-7793
11
Kondo S,
Kisiel W.
Evidence that plasma lipoproteins inhibit the factor VII a-tissue factor complex by a different mechanisms than extrinsic pathway inhibitor. Blood 1987; 70: 1947-1954
12
Stem DM,
Nawroth PP,
Kisiel W,
Handley D,
Drillings M,
Bantos J.
A coagulation pathway on bovine aortic segments leading to generation of factor Xa and thrombin. J Clin Invest 1984; 74: 1910-1921
15
Wildgoose P,
Berkner KL,
Kisiel W.
Synthesis, purification, and characterization of an Argl52 Glu site directed mutant of recombinant human blood clotting factor VII. Biochemistry 1990; 29: 3413-3420
16
Komiyama Y,
Pedersen AH,
Kisiel W.
Proteolytic activation of human factors IX and X by recombinant human factor Vila. Effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9148-9125
17
Bach R,
Gentry R,
Nemerson Y.
Factor VII binding to tissue factor in reconstituted phospholipid vesicles: Induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-4020
18
Wildgoose P,
Kazim AL,
Kisiel W.
The importance of residues 195-206 of human blood clotting factor VII in the interaction of factor VII with tissue factor. Proc Natl Acad Sci USA 1990; 87: 7290-7294
20
Kazen A,
Glick M.
Oxytocin, Methods of Hormone Radioimmunoassay. Jaffe and Behrmann; New York: 1979. p 328
21
Akiyama H,
Sinha D,
Seaman FS,
Kirby EP,
Walsh PN.
Mechanism of activation of coagulation factor XI by factor XII a studied with monoclonal antibodies. J Clin Invest 1986; 78: 1631-1636
26
Nawroth PP,
Kisiel W,
Stem DM.
Anticoagulant and antithrombotic properties of a ³-carboxyglutamic acid-rich peptide derived from the light chain of blood coagulation factor X. Thromb Res 1986; 44: 625-637
27
Rao LVM,
Rapaport SI,
Tait JF.
Role of negatively charged phospholipids in Vila- catalyzed activation of FX on the cell surface. Circulation 1990; 82: III-132 (abstract)